Published in Vaccine Weekly, August 25th, 2004
"We have previously demonstrated that it is possible to effectively vaccinate against long-term murine gamma herpesvirus 68 (gammaHV68) latency by using a reactivation-deficient virus as a vaccine. Immune antibody was capable of recapitulating aspects of this vaccination. This led us to determine whether antibody is required for vaccination against latency. Using mice lacking antigen-specific antibody responses, we demonstrate here that antibody and B cells are not required for vaccination against latency," investigators in the United States...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly